Imagion Biosystems announces an amendment to the previously announced close date. For the purposes of the Pro-Rata Renewable Rights Issue, the indicative close date is Friday, 15 November 2019.
Read the amendment.
Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway
September 9, 2025
Highlights Dr Nina Webster appointed as IBX Non-Executive Director, bringing significant clinical development expertise and corporate experienceto the IBX Board ahead of HER2 Breast cancer